Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Data on diagnostic performance of Galactomannan (GM) testing in patients under mould‐active regimens are limited. Whether sensitivity of GM testing for diagnosing breakthrough invasive aspergillosis (IA) is decreased under antifungal prophylaxis/therapy remains therefore a point of discussion. We retrospectively analysed GM test results in patients who were admitted with underlying haematological malignancies to two Divisions of the Medical University Hospital of Graz, Austria, between 2009 and 2012. Only cases of probable and proven IA that were diagnosed by other methods than GM testing were included (time of diagnosis = day 0). We compared GM results of patients with/without therapy/prophylaxis for the period of 2 weeks prior (week −2) until 3 weeks postdiagnosis. A total of 76 GM test results in nine patients were identified. Six patients had received antifungal therapy/prophylaxis from week −2, whereas three patients were treated with therapy from the time of diagnosis at week 0. GM testing was positive in 45/76 (59%) of samples. Sensitivity of GM testing for detection of proven or probable IA at week −1 and 0 was 77% and 79% in patients with mould‐active regimens. We conclude that GM testing might be a useful diagnostic method for breakthrough IA in patients receiving mould‐active prophylaxis/therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Haese, J., Theunissen, K., Vermeulen, E., Schoemans, H., De Vlieger, G., Lammertijn, L., Meersseman, P., Meersseman, W., Lagrou, K., & Maertens, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06423-11 · Cited by 186
Reinwald, M., Spiess, B., Heinz, W. J., Vehreschild, J. J., Lass‐Flörl, C., Kiehl, M., Schultheis, B., Krause, S. W., Wolf, H., Bertz, H., et al. (2012) · European Journal of Haematology · doi:10.1111/j.1600-0609.2012.01806.x · Cited by 67
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Hoenigl, M., Prattes, J., Spiess, B., Wagner, J., Prueller, F., Raggam, R. B., Posch, V., Duettmann, W., Hoenigl, K., Wölfler, A., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00467-14 · Cited by 233
Self-citationBreakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Self-citationAn update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
Self-citationJenks, J. D., Gangneux, J.-P., Schwartz, I. S., Alastruey-Izquierdo, A., Lagrou, K., Thompson III, G. R., Lass-Flörl, C., Hoenigl, M., & Investigators, E. C. O. M. M. (. C. (2020) · Journal of Fungi · doi:10.3390/jof6040216 · Cited by 44
“In addition, conventional biomarkers that have become the mainstay of diagnosis of invasive fungal infections and invasive aspergillosis, such as 1,3-β-d-glucan (BDG) and galactomannan (GM), respectively, are negatively influenced in patients receiving mold-active prophylaxis or treatment (5-9).”
BackgroundSelf-citation
Metadata
- Authors
- Hoenigl, M., Seeber, K., Koidl, C., Buzina, W., Wölfler, A., Duettmann, W., Wagner, J., Strenger, V., & Krause, R.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2013-02-24
- Volume
- 56
- Issue
- 4
- Pages
- 471-476
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W1998256933
- Cited by
- 42
- References
- 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. https://app.cochat.ai/papers/10.1111/myc.12060
- The paper
- Hoenigl, M., Seeber, K., Koidl, C., Buzina, W., Wölfler, A., Duettmann, W., Wagner, J., Strenger, V., & Krause, R. (2013). Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Mycoses. https://doi.org/10.1111/myc.12060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.